Zhu C - Search Results

1

Expression of CDK7 correlates with molecular subtypes and predicts clinical outcomes in breast cancer.

Tang L, Zhu C, Jin J, Wang X, Yu L, Guan X. Tang L, et al. Among authors: zhu c. Transl Cancer Res. 2021 Feb;10(2):669-680. doi: 10.21037/tcr-20-2911. Transl Cancer Res. 2021. PMID: 35116400 Free PMC article.

2

MYC dysfunction modulates stemness and tumorigenesis in breast cancer.

Liu Y, Zhu C, Tang L, Chen Q, Guan N, Xu K, Guan X. Liu Y, et al. Among authors: zhu c. Int J Biol Sci. 2021 Jan 1;17(1):178-187. doi: 10.7150/ijbs.51458. eCollection 2021. Int J Biol Sci. 2021. PMID: 33390842 Free PMC article.

3

Heterogeneity of CTC contributes to the organotropism of breast cancer.

Yu T, Wang C, Xie M, Zhu C, Shu Y, Tang J, Guan X. Yu T, et al. Among authors: zhu c. Biomed Pharmacother. 2021 May;137:111314. doi: 10.1016/j.biopha.2021.111314. Epub 2021 Feb 12. Biomed Pharmacother. 2021. PMID: 33581649 Free article. Review.

4

Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis.

Xu K, Wang R, Xie H, Hu L, Wang C, Xu J, Zhu C, Liu Y, Gao F, Li X, Wang C, Huang J, Zhou W, Zhou G, Shu Y, Guan X. Xu K, et al. Among authors: zhu c. Oncogenesis. 2021 Oct 5;10(10):66. doi: 10.1038/s41389-021-00355-6. Oncogenesis. 2021. PMID: 34611125 Free PMC article.

5

Circulating Tumor Cells and Breast Cancer Metastasis: From Enumeration to Somatic Mutational Profile.

Zhu C, Xu J, Sun J, Cui S, Sun Y, Yu T, Wang C, Wang T, Wu Y, Ju F, Yao J, Liu K, Zhang W, Guan X. Zhu C, et al. J Clin Med. 2022 Oct 14;11(20):6067. doi: 10.3390/jcm11206067. J Clin Med. 2022. PMID: 36294386 Free PMC article.

6

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.

Li X, Tang L, Chen Q, Cheng X, Liu Y, Wang C, Zhu C, Xu K, Gao F, Huang J, Wang R, Guan X. Li X, et al. Among authors: zhu c. Chin Med J (Engl). 2022 Oct 20;135(20):2436-2445. doi: 10.1097/CM9.0000000000002329. Chin Med J (Engl). 2022. PMID: 36583862 Free PMC article.

7

Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.

Sun Y, Zhu C, Xu F, Cui S, Guan X. Sun Y, et al. Among authors: zhu c. Clin Breast Cancer. 2023 Jun;23(4):339-349. doi: 10.1016/j.clbc.2023.02.012. Epub 2023 Mar 2. Clin Breast Cancer. 2023. PMID: 36966079 Review.

8

c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer.

Li X, Zhang Z, Gao F, Ma Y, Wei D, Lu Z, Chen S, Wang M, Wang Y, Xu K, Wang R, Xu F, Chen JY, Zhu C, Li Z, Yu H, Guan X. Li X, et al. Among authors: zhu c. J Am Chem Soc. 2023 Apr 26;145(16):9334-9342. doi: 10.1021/jacs.3c02619. Epub 2023 Apr 17. J Am Chem Soc. 2023. PMID: 37068218

9

Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.

Xu F, Xu K, Fan L, Li X, Liu Y, Yang F, Zhu C, Guan X. Xu F, et al. Among authors: zhu c. Chin Med J (Engl). 2024 Feb 5;137(3):338-349. doi: 10.1097/CM9.0000000000002930. Epub 2023 Dec 15. Chin Med J (Engl). 2024. PMID: 38105538 Free PMC article.

10

Hypoxia stimulates CTC-platelet cluster formation to promote breast cancer metastasis.

Zhou W, Zhu C, Shen P, Wang JF, Zhu G, Jia Y, Wu Y, Wang S, Sun J, Yang F, Song Y, Han X, Guan X. Zhou W, et al. Among authors: zhu c, zhu g. iScience. 2024 Mar 20;27(5):109547. doi: 10.1016/j.isci.2024.109547. eCollection 2024 May 17. iScience. 2024. PMID: 38660400 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,645 results

Search Page

Filters